CANADIAN HEALTH POLICY JOURNAL HIGHLIGHTS Audio & VideoVIDEO – Who needs National Pharmacare? Audio & VideoVIDEO – What good is National Pharmacare? Audio & VideoVIDEO – Who will pay for National Pharmacare? News & AnnouncementsGlobe and Mail, CBC, Global News cite CHPI research on cross-border re-sale risks to Canada’s drug supply Latest Articles Canadian public payer best practices for providing timely patient access to cancer therapies Judith Glennie BScPhm MSc PharmD; Kathleen Gesy; Yen Nguyen BPharm Adapting the Safe Consumption Site Model for Patient-Procured MDMA Shannon Dames RN MPH EdD; Crosbie Watler MD; Kerrie Miller RN; Robert W.E. Laurie LLB; Vivian W.L. Tsang MD; Raimey Olthuis PhD; Pearl Allard RN; Elena Argento PhD; Pam Kryskow MD The Supply of Primary Care Physicians in Alberta 2018-2022 – A Dire Description Terrence McDonald, MD, MSc; Jessie Hart Szostakiwskyj, MSc; Lee A. Green, MD, MPH | University of Calgary; University of Alberta | 2023 Toward a Policy Framework to Improve the Health Care of Homeless Individuals Kirk A Collins, PhD | Trent University | 2023 Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021 Nigel S B Rawson, PhD; Brett J Skinner, PhD | Canadian Health Policy Institute | 2023 Herceptin® treatments in hospital and at CLSCs for breast cancer patients in Quebec: comparative analysis of costs and care trajectories. Gerald Batist, MD; Geneviève Faucher, MD; Sonia Joannette, RN; Yanick Labrie, MA; Giovanna Speranza, MD | 2023 Traitements d’Herceptin© à l’hôpital et en CLSC pour les patientes atteintes de cancer du sein au Québec: analyse comparative des coûts et des trajectoires de soins. Gerald Batist, MD; Geneviève Faucher, MD; Sonia Joannette, RN; Yanick Labrie, MA; Giovanna Speranza, MD | 2023 New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage. Brett Skinner PhD | Canadian Health Policy Institute | 2023 Economic burden of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation. Brett Skinner PhD | Canadian Health Policy Institute | 2023 Policy approaches for increasing participation with personal health information and data sharing (HIDS) Daniel J. Caron PhD; Vincent Nicolini, PhD; Alexandre Prud’homme | École nationale d'administration publique (ENAP); Carleton University; Université de Montréal | MAR 2023 Latest Opinions Government hostility to biopharmaceutical industry reduces access to innovative drugs Nigel Rawson and John Adams | Hill Times | Nov 15, 2023 Pharmacare won’t help Canadians with rare disorders Nigel Rawson and John Adams | Financial Post | Nov 07, 2023 Canada has in fact achieved universal drug insurance coverage Brett Skinner PhD | Toronto Star | 2023 Lower drug prices are a good thing. Canada’s approach to achieving them was not. Nigel Rawson PhD | Globe and Mail | 2023 The drug prices review board was once a solution. It’s now a problem: Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada Nigel Rawson PhD and John Adams | Financial Post | 2023 For drug access, Canadians with rare disorders are 40 years behind Americans Nigel Rawson PhD and John Adams | Financial Post | 2023 Suffer from a rare disorder in Canada? Good luck Nigel Rawson PhD and John Adams | Financial Post | 2022 Uncertainty about PMPRB price regulations will deter new drug launches in Canada Nigel Rawson PhD and Brett Skinner PhD | Hill Times | 2022 New patented medicines regulations reflect the general evidence deficiency in Canadian pharmaceutical policy Brett Skinner PhD | Financial Post, Hill Times | 2022 National drug plan process doesn’t add up Nigel Rawson | Hamilton Spectator | 17 FEB 2022 Stay updated with our Email Newsletter Sign-up to E-News for instant updates on CHPI research, opinions, events and advocacy. First Name Last Name Email AddressTelephone Number Sign-Up News & Announcements Globe and Mail, CBC, Global News cite CHPI research on cross-border re-sale risks to Canada’s drug supply 4 April 2023 Audio & Video VIDEO – Who needs National Pharmacare? 21 AUG 2023 VIDEO – What good is National Pharmacare? 21 AUG 2023 VIDEO – Who will pay for National Pharmacare? 21 AUG 2023 AUDIO – Brett Skinner talks about dangerous new drug price regulations CFMJ AM640 Toronto 7 February 2020 AUDIO – CHPI CEO talks Pharmacare on CKLW AM800 Windsor 11 November 2019 AUDIO – GLOBAL NEWS AM770 Calgary – Danielle Smith interviews Brett Skinner about pharmacare 6 June 2019 VIDEO – National Pharmacare is unnecessary, bad for patients, and costly for taxpayers. 4 February 2019 information and ideas for a better health system ISSN 2562-9492
